Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer ; volume:41 ; number:6 ; day:21 ; month:9 ; year:2024 ; pages:937-945 ; date:12.2024
Clinical & experimental metastasis ; 41, Heft 6 (21.9.2024), 937-945, 12.2024
- Creator
-
Welsch, Eva
Bonstingl, Lilli
Holzer, Barbara
Schuster, Eva
Weiß, Esther
Zaharie, Alexandru-Teodor
Krainer, Michael
Fischer, Michael B.
El-Heliebi, Amin
Zeillinger, Robert
Obermayr, Eva
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10585-024-10313-2
- URN
-
urn:nbn:de:101:1-2503012123572.417424676262
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Welsch, Eva
- Bonstingl, Lilli
- Holzer, Barbara
- Schuster, Eva
- Weiß, Esther
- Zaharie, Alexandru-Teodor
- Krainer, Michael
- Fischer, Michael B.
- El-Heliebi, Amin
- Zeillinger, Robert
- Obermayr, Eva
- SpringerLink (Online service)
Other Objects (12)
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Transport costs, intermediate goods, and localized growth
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hypofractionated radiotherapy for localized prostate cancer
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
Treatment of metastatic lesions localized in the acetabulum
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Transport costs, intermediate goods, and localized growth
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hypofractionated radiotherapy for localized prostate cancer
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
Treatment of metastatic lesions localized in the acetabulum
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Transport costs, intermediate goods, and localized growth
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hypofractionated radiotherapy for localized prostate cancer
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer